PMID- 29387244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 1
DP  - 2018 Jan
TI  - miR-144 suppresses proliferation and induces apoptosis of osteosarcoma cells via 
      direct regulation of mTOR expression.
PG  - 1163-1169
LID - 10.3892/ol.2017.7364 [doi]
AB  - Studied as a type of tumor suppressor, microRNA (miR) performs an important role 
      in growth and apoptosis of various human carcinomas. However, the effects of 
      miR-l44 on osteosarcoma growth and apoptosis, as well as possible underlying 
      mechanisms, remain unclear. The present study investigated the expression of 
      miR-144 in osteosarcoma MG-63 and U-2 OS cell lines compared with osteoblast 
      cells. In order to elucidate the effects of miR-144 on osteosarcoma, miR-144 was 
      upregulated in MG-63 and U-2 OS cells by transfecting chemically synthesized 
      miR-144 mimics. Bioinformatics analysis of potential miR-144 target genes was 
      performed using TargetScanHuman 7.0 and confirmed by luciferase assay. This 
      analysis identified mammalian target of rapamycin (mTOR) as a target of miR-144. 
      The present results indicated that the overexpression of miR-144 may 
      significantly inhibit proliferation and promote apoptosis of MG-63 and U-2 cells 
      compared with scramble control. Furthermore, the effects of miR-144 on 
      osteosarcoma were associated with the mTOR signaling pathway via directly 
      targeting the 3' untranslated region of mTOR mRNA, resulting in a decrease in the 
      level of mTOR protein. In summary, miR-144 was demonstrated to act as a tumor 
      suppressor, which inhibits proliferation and promotes apoptosis of osteosarcoma 
      cell lines. In addition, this effect was mediated by direct targeting on mTOR 
      following inhibition of the mTOR signaling pathway. The present study suggested 
      that miR-144 may be a candidate for the gene therapy of osteosarcoma.
FAU - Ren, Yuan-Fei
AU  - Ren YF
AD  - Department of Hand and Foot Surgery, Dalian Municipal Central Hospital, Dalian, 
      Liaoning 116033, P.R. China.
FAU - Zhang, Tie-Hui
AU  - Zhang TH
AD  - Department of Hand and Foot Surgery, Dalian Municipal Central Hospital, Dalian, 
      Liaoning 116033, P.R. China.
FAU - Zhong, Sheng
AU  - Zhong S
AD  - Department of Hand and Foot Surgery, Dalian Municipal Central Hospital, Dalian, 
      Liaoning 116033, P.R. China.
FAU - Zhao, Yan-Tao
AU  - Zhao YT
AD  - Department of Hand and Foot Surgery, Dalian Municipal Central Hospital, Dalian, 
      Liaoning 116033, P.R. China.
FAU - Lv, Ya-Nan
AU  - Lv YN
AD  - Department of Radiology, Dalian Municipal Central Hospital, Dalian, Liaoning 
      116033, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20171108
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5768133
OTO - NOTNLM
OT  - gene therapy
OT  - mammalian target of rapamycin signaling pathway
OT  - microRNA-144
OT  - osteosarcoma
EDAT- 2018/02/02 06:00
MHDA- 2018/02/02 06:01
PMCR- 2017/11/08
CRDT- 2018/02/02 06:00
PHST- 2015/12/04 00:00 [received]
PHST- 2017/05/11 00:00 [accepted]
PHST- 2018/02/02 06:00 [entrez]
PHST- 2018/02/02 06:00 [pubmed]
PHST- 2018/02/02 06:01 [medline]
PHST- 2017/11/08 00:00 [pmc-release]
AID - OL-0-0-7364 [pii]
AID - 10.3892/ol.2017.7364 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Jan;15(1):1163-1169. doi: 10.3892/ol.2017.7364. Epub 2017 Nov 8.